Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

BG Medicine Receives CE Mark For Galectin-3 Blood Test

BG Medicine (BGM), a privately-held developer of biomarker-based in vitro diagnostics, has launched new, CE-marked test for the measurement of galectin-3 in human plasma or serum, in the EU.

Galectin-3 has been shown by researchers at the University of Maastricht, the Netherlands, to play an integral role in the development and progression of heart failure.

The company said that Galectin-3 is a protein that is involved in the biological processes leading to cardiac fibrosis and scarring, which play a role in heart failure development and progression. Several studies have shown that galectin-3 may provide insight about heart failure and its underlying disease processes.

The BGM Galectin-3 test is available for clinical use in the EU and certain other European countries as an aid in the stratification of patients diagnosed with heart failure. The BGM Galectin-3 test is not available for sale or distribution in the US or Canada. The company has submitted a 510(k) application to obtain clearance from the FDA to sell the test in the US.

Pieter Muntendam, president and CEO of BG Medicine, said: “This is an important point in our development of galectin-3 testing and a milestone for the company. The objective of our BGM Galectin-3 test is to redefine heart failure on the basis of underlying disease processes, not as it is currently addressed based solely on the nature and severity of signs or symptoms.”